Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 22;9:307. doi: 10.1038/s41392-024-02028-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Combination therapy vaccinates tumor in situ for distal tumor control. a Therapeutic time schedule for intratumor phenotyping. b Representative flow cytometry graphs and statistical analysis of intratumor CD45⁺ immune cell percentage (n = 6 biologically independent animals). c Representative flow cytometry graphs and statistical analysis of intratumor CD206⁺ macrophage fraction among tumor-resident macrophages (n = 6 biologically independent animals). d Representative flow cytometry graphs and statistical analysis of intratumor CD80⁺ CD86⁺ matured DC fraction in tumor-resident DCs (n = 6 biologically independent animals). e Heat map of intratumor cytokine and chemokine in different groups. Data are calculated by log2 fold change in comparison with the average of the OT-I group, n = 3 biological independent animals. f Therapeutic schedule for double flank murine melanoma treatment. g Tumor volume monitoring and statistical analysis of the primary tumors (n = 5–7 biologically independent animals). h Tumor volume monitoring and statistical analysis of the distal tumors (n = 5–7 biologically independent animals). Data are shown as mean ± s.d. P values were determined by one-way ANOVA with a Tukey post hoc test